Kiadis’ ATIR Boosts Long-term Survival in Phase I/II HSCT Trial
By Nuala Moran
Staff Writer
Staff Writer
LONDON – Kiadis Pharma BV announced positive results in a five-year follow-up of the Phase I/II study of ATIR, a cell therapy for enabling hematopoietic stem cell transplants from non-identical donors.
